CNS accumulation of regulatory B cells is VLA-4-dependent
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 15, 2015
- Accepted in final form January 7, 2016
- First Published March 9, 2016.
Author Disclosures
- Klaus Lehmann-Horn, MD,
- Sharon A. Sagan, BA,
- Ryan C. Winger, PhD,
- Collin M. Spencer, BS,
- Claude C.A. Bernard, PhD,
- Raymond A. Sobel, MD and
- Scott S. Zamvil, MD, PhD
- Klaus Lehmann-Horn, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Fellowship grant from the Deutsche Forschungsgemeinschaft (DFG; Le 3079/1-1)
NONE
Fellowship grant from the US National Multiple Sclerosis Society (FG 2067-A-1)
NONE
NONE
NONE
NONE
NONE
NONE
- Sharon A. Sagan, BA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ryan C. Winger, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Collin M. Spencer, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claude C.A. Bernard, PhD,
NONE
NONE
NONE
(1) Future Neurology, Future Science Group. Editorial Board Member.Current (2) Inflammation and Regeneration. Guest Editor. 2014 (3) Inflammation and Regeneration. Editorial Board 2013
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NHMRC of Australia; APP1048899;PI, 2013-2015 NHMRC of Australia; APP1069979; PI, 2014-1016 NHMRC of Australia/CIRM; APP1053621, PI, 2012-2015 Victorian Goverment/CIRM; RMI-01739, PI, 2012-2015 Department of Industry,Commonwealth of Australia, 2013-2016
NONE
Eva and Les Erdi AUSiMED Fellowship in Neurological Diseases.
NONE
NONE
NONE
NONE
NONE
NONE
- Raymond A. Sobel, MD and
NONE
NONE
NONE
Journal of Neuropathology and Experimental Neurology, Editor-in-Chief, 2007-present, Journal of Neuroimmunology, Associate Editor, 2000-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH R01 NS 030843. (PI: V. Kuchroo, subcontract to Dr. Sobel as Co-Investigator (2002-2014) NIH/NIAID R01 AI073737 (PI: S. Zamvil, Subcontract to Dr. Sobel as Co-Investigator) 6/1/09 ? 6/31/14. DOD/CDRMP W81XWH-11-1-0512. PI: B. Zabel. Dr. Sobel is Co-Investigator 9/1/11-8/31/14
NONE
National Multiple Sclerosis Society (PI: Zamvil)
NONE
NONE
NONE
NONE
NONE
NONE
- Scott S. Zamvil, MD, PhD
Dr. Zamvil has received honoraria for serving on Data Safety Monitoring Boards for MS trials conducted by BioMS, Teva Pharmaceuticals, Inc. and Eli Lilly and Co. He is a member of the Clinical Advisory Board for the Myelin Repair Foundation.
NONE
NONE
(1) Neurology, Neuroimmunology and Neuroinflammation, Deputy Editor, 2014-present
NONE
NONE
NONE
SSZ has served as a consultant to Biogen Idec, Teva Neuroscience, EMD-Serono, Genzyme, Novartis and Roche.
Advanced Health Media, 2009-present Biogen Idec, 2009-present
NONE
NONE
NONE
NIH RO1 AI073737 NIH RO1 NS 063008
NMSS RG 4768A9/1 NMSS RG 5180A11/1 NMSS RG 5179A10/2
Alexander M. and June L. Maisin Foundation, PI
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology and Program in Immunology (K.L.-H., S.A.S., R.C.W., C.M.S., S.S.Z.), University of California, San Francisco; Multiple Sclerosis Research Group (C.C.A.B.), Australian Regenerative Medicine Institute, Monash University, Clayton, Australia; and Department of Pathology (R.A.S.), Stanford University School of Medicine, CA. Dr. Lehmann-Horn is currently with the Department of Neurology, Klinikum rechts der Isar, Technische Universität München; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
- Correspondence to Dr. Zamvil: zamvil{at}ucsf.neuroimmunol.org
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.